文献速递肝病

门诊腹腔穿刺后静脉输注白蛋白可降低AKI住院风险:一项全国队列研究

Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study.
PubMed 文献 · Hepatology · 2026-03-11

该回顾性队列研究基于退伍军人肝硬化队列,纳入9467例患者共56941次门诊腹腔穿刺操作,其中17%使用了静脉白蛋白。白蛋白使用与AKI相关住院风险降低相关(OR 0.66,95%CI 0.54-0.81,p<0.001),在估算肾小球滤过率较低的患者中效应更明显。

要点

  • 门诊腹腔穿刺后使用静脉白蛋白与AKI相关住院风险降低独立相关。
  • 低eGFR患者使用白蛋白的获益更显著(交互作用p=0.03)。
  • 较高剂量白蛋白(≥6-8 g/L移除液)与更低的AKI住院风险相关。

核心结论

  • 门诊腹腔穿刺后静脉输注白蛋白与AKI相关住院风险降低相关,且在eGFR较低的患者中效应更强。

研究设计与样本

  • 回顾性队列研究,纳入退伍军人肝硬化患者9467例,共56941次门诊腹腔穿刺操作。

主要发现

  • 静脉白蛋白使用率为17%。
  • 白蛋白使用与AKI相关住院风险降低相关(OR 0.66,95%CI 0.54-0.81,p<0.001)。
  • 在eGFR较低患者中白蛋白效应更明显(交互作用p=0.03)。
  • 在48401次有剂量信息的操作中,较高剂量白蛋白(≥6-8 g/L移除液)与更低的AKI住院风险相关(OR 0.36,95%CI 0.20-0.64,p=0.001)。

关键数值与推荐

  • 白蛋白使用率随MELD-Na评分升高而增加(OR 1.02,95%CI 1.02-1.03,p<0.001)。
  • eGFR<30 vs ≥90 mL/min/1.73 m²的OR为3.06(95%CI 2.64-3.54,p<0.001)。
  • 肝性脑病与白蛋白使用相关(OR 1.22,95%CI 1.13-1.33,p<0.001)。

临床怎么用

  • 门诊腹腔穿刺后可考虑静脉输注白蛋白以降低AKI住院风险,尤其对eGFR较低患者。
  • 较高剂量白蛋白(≥6-8 g/L移除液)可能带来更大获益,但需前瞻性验证。

局限性

  • 回顾性设计可能残留混杂。
  • 白蛋白使用非随机分配,存在适应证偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Guidelines recommend i.v. albumin after large-volume paracentesis to prevent postparacentesis circulatory dysfunction and acute kidney injury (AKI). However, real-world effects of albumin on paracentesis outcomes in outpatient settings are understudied. We aimed to address this using national data from a well-established cirrhosis cohort. APPROACH AND RESULTS: This was a retrospective cohort study of Veterans with cirrhosis undergoing outpatient paracentesis. Albumin administration and paracentesis volumes were extracted, in addition to hospitalization for AKI within 7 days of outpatient paracentesis. Mixed-effects logistic regression identified factors associated with albumin administration and the association between albumin and incident AKI hospitalization. Among 9467 patients who received 56,941 outpatient paracentesis procedures, i.v. albumin was used 17% of the time. The use was higher with Model for End-Stage Liver Disease-Sodium; (OR: 1.02, 95% CI: 1.02-1.03, p <0.001), lower estimated glomerular filtration rate (OR: 3.06 for <30 vs. ≥90 mL/min/1.73 m 2 , 95% CI: 2.64-3.54, p <0.001), and HE (OR: 1.22, 95% CI: 1.13-1.33, p <0.001). Albumin administration was associated with lower odds of AKI-related hospitalizations (OR: 0.66, 95% CI: 0.54-0.81, p <0.001), with a greater effect observed in patients with lower estimated glomerular filtration rate (interaction p value=0.03). In a subcohort of 48,401 procedures with available dosing information, higher-dose albumin (≥6-8 g/L removed) was associated with lower odds of AKI hospitalization (OR:: 0.36, 95% CI:: 0.20-0.64, p =0.001) with similar associations noted irrespective of paracentesis volume. CONCLUSIONS: Albumin administration after outpatient paracentesis was associated with a reduced risk of hospitalization with AKI, with a greater effect at lower estimated glomerular filtration rates. Strategies that tailor albumin administration based on intravascular volume and hemodynamics should be prospectively tested.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mahmud N, Schechter MS, Zhang S, et al. Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study. Hepatology. 2026. PMID: 41918411. doi:10.1097/HEP.0000000000001739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。